Sonnet biotherapeutics provides fiscal year 2023 second quarter and year-to-date business and earnings update

Additional data presented from two clinical trials of son-1010 in both healthy volunteers and patients with advanced solid tumors. cytokine data reveal extended pk profile for son-1010: induces prolonged and controlled ifnΓ response no evidence of cytokine release syndrome clinical benefit was seen in 36% of patients (5/14) with advanced solid tumors entered into a collaboration with roche for the clinical evaluation of son-1010 with atezolizumab (tecentriq®) in ovarian cancer with study initiation currently underway announced data from two ind-enabling toxicology studies with son-1210 in non-human primates doses were well tolerated at over 50 times the anticipated human dose successfully completed a $15.0 million underwritten public offering princeton, nj / accesswire / may 10, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months and six months ended march 31, 2023 and provided a business update.
SONN Ratings Summary
SONN Quant Ranking